Abstract Although estradiol (E 2 ) may have some beneficial effects as a treatment for menopause symptoms, E 2 also has trophic effects that can increase vulnerability to some cancers, such as breast cancer. In the present study, a model to investigate the concomitant behavioral and proliferative effects of E 2 was developed. First, the effects of different duration of chronic E 2 exposure (2 vs 6 months), or no such exposure, on proliferation (tumor incidence and weight, uterine weight) in adult, ovariectomized (OVX) rats was determined. Second, the effects of different dosages of E 2 (0.03 or 0.09 mg/kg) compared to vehicle only on sexual behavior, and measures of proliferation of adult OVX rats treated with a chemical carcinogen (DMBA; 1.25, 12.50, or 25.00 mg), or inert vehicle, were investigated. Vehicle or E 2 was administered subcutaneously (SC) to OVX rats once per week for 14 weeks. Six months of continuous E 2 exposure increased tumor incidence, tumor weight, and uterine weight, compared to 2 months of E 2 or no E 2 exposure. Rats administered DMBA had increased incidence, number, and size of tumors compared to vehicle treatment, and this effect appeared to be augmented by E 2 . Compared to vehicle, E 2 increased lordosis and uterine weight. Thus, E 2 may have the unfavorable effect of increasing proliferation when administered in chronic situations. Studies investigating the action of E 2 for these effects are ongoing.
many women are living typically one-third to one-half of their lives in a 17β-estradiol (E 2 )-deficient state (Minino et al. 2007 ). Ovarian cessation in E 2 production can be associated with physical symptoms and changes in quality-of-life/psychological measures (e.g., hot flushes, night sweats, genital dryness, cognition, anxiety, and mood changes) that can be relieved with E 2 -based therapies in some women. However, in recent years, following the publication of some of the negative findings from a large randomized controlled trial-the Women's Health Initiative (WHI)-the benefits of the use of E 2 -based treatments in relation to their potential risks have been questioned and women have begun to reconsider their treatment options for alleviating menopausal symptoms (Rapp et al. 2003; Rossouw et al. 2002; Shumaker et al. 2003) .
E 2 is a pleiotropic hormone that results in growth and differentiation. Acting as a mitogen it promotes breast and endometrial tumors, which account for ∼40% of cancer incidence among women. The role of E 2 to increase risk for breast cancer is widely recognized, and greater breast cancer risk has been shown to be associated with high serum E 2 (Clemons and Goss, 2001; Toniolo et al. 1995; Thomas et al. 1997; Cauley et al. 1999; Hankinson et al. 1998 ) and administration of exogenous E 2 to postmenopausal women (Collaborative Group on Hormonal Factors in Breast Cancer, 1997; Magnusson et al. 1999; Colditz et al. 1995) . A history of greater exposure to E 2 , such as occurs related to parity, early age of menarche, and late-onset menopause (Hulka 1996) , is associated with an increased breast cancer risk (Hulka 1996; Lambe et al. 1996; Madigan et al. 1995; Ramon et al. 1996) . Breast cancer risk also tends to be increased by other factors that increase circulating E 2 levels, such as obesity (Thomas et al. 1997) . Furthermore, bilateral oophorectomy reduces endogenous E 2 levels and breast cancer risk in premenopausal women (Schairer et al. 1997; Meijer and van Lindert 1992) . Although E 2 can be beneficial in reducing symptoms of menopause among some women, inconsistencies in these effects, and the association between E 2 and breast cancer risk remains a concern for postmenopausal women, ultimately reducing the enthusiasm for their use as treatment options.
Some of these limitations in the clinical studies of E 2 for its functional effects have been explored using animal models. A typical approach taken to model menopause and the effects of E 2 is ovariectomy (OVX), the surgical removal of the main endogenous source of E 2 -the ovaries. For example, compared to young proestrous rats (with high physiological E 2 levels), OVX increases anxiety and depressive behavior and decreases sexual responding of rats (Frye et al. 1998 ; reviewed in Walf and Frye 2006; 2005b) . These effects can be reversed with E 2 administration, but the magnitude of the response is influenced by dosing and/or the E 2 regimen utilized (reviewed in Walf and Frye 2006) . Given the role of E 2 for functional and trophic processes, it is important to design an animal model in which the effects of E 2 for behavior and proliferation can be characterized concomitantly, and to determine whether there are differences in the potency of E 2 's effects for these processes. In Experiment 1, the duration of chronic E 2 exposure (i.e., 0, 2, or 6 months) associated with increased proliferation was determined. In Experiment 2, the dose-dependent effects of E 2 , administered once weekly for 3.5 months, on sexual behavior and proliferation were determined. Specifically, in this experiment, OVX rats were administered different dosages of E 2 (0, 0.03, or 0.09 mg/kg) and/or the chemical carcinogen 7, 12-dimethylbenz(a) anthracene (DMBA; 1.25, 12.50, 25.00 mg) or an inert control substance. Other studies have demonstrated dose and/or duration-dependent effects of DMBA for mammary and ovarian hyperplasia (Stewart et al. 2004; Ting et al. 2007 ). Sexual responding and proliferation (incidence of tumors, tumor weight, and uterine weight) were determined 3.5 months post-DMBA. We hypothesized that there would be duration and/or dose-responsive effects of E 2 and/or DMBA on behavior and/or proliferation.
Materials and methods
All methods utilized have been approved by the Institutional Animal Care and Use Committee at University at Albany-SUNY, and were performed in accordance with accepted standards of humane animal use.
Animals and housing
Subjects (n=66) were adult (4-8 months of age) female rats that were obtained from our breeding colony (original stock from Taconic Farms; Germantown, NY). Rats were group-housed (3-5 per cage) in polycarbonate cages (45×24×21 cm), containing woodchip shavings for bedding, in a temperature-controlled room (21 ± 1°C) in the Laboratory Animal Care Facility of The Life Sciences Research Building at The University at Albany-SUNY. Rats were maintained on a 12/12-h reversed light cycle (lights off at 8:00 a.m.) with ad libitum access to Rodent Chow and tap water in their home cages.
Procedure
In Experiment 1, the duration of chronic E 2 exposure that would produce measurable proliferative effects was determined. The rationale for this study was that we have previously observed an increased likelihood of rats that are OVX at 2-3 months of age and then administered chronic E 2 implants for typically 6-12 months to develop tumors, compared to control rats (OVX and not E 2 -replaced). As such, in the present study, we used a similar approach to compare the incidence of tumors and uterine weights in OVX rats that had not been exposed to E 2 (n=4), exposed to E 2 via chronically implanted silastic capsules filled with E 2 for 2 months (n=4) or 6 months (n=6). Tissues were collected when rats were 4-8 months of age. In this experiment, the possible dose-dependent effects of E 2 on proliferation were not determined and this is of interest. However, the high incidence of tumors in rats that were chronically administered E 2 for 6 months substantiated using a shorter (3.5 months versus 6) and less chronic (weekly SC injections vs implants) E 2 exposure paradigm so that dose-dependent effects could be determined. Furthermore, in Experiment 2, rats were administered the chemical carcinogen DMBA, and we based the length of the present study on several published reports (Cheung et al. 2003; Russo et al. 1990; Russo 1996, 1998; Ting et al. 2007 ). As such, in Experiment 2, whether there were additive effects of E 2 and carcinogen exposure for proliferation (i.e., tumorigenesis, uterine weight) and socio-sexual behavior was determined. Rats were OVX at 2 months of age and randomly assigned to 1 of 12 experimental groups (n=3-5/group). Rats were administered DMBA once and then E 2 weekly. In week 6 of the protocol, rats were tested for sexual receptivity on one occasion 44-48 h after E 2 -priming. At 3.5 months after administration of DMBA, or the inert control substance, tumors (if present) and uterine tissue of rats were collected and weighed. Details of the methodology utilized are included in the following sections.
Ovariectomy
All rats were OVX under xylazine (12 mg/kg; Bayer, Shawnee Mission, KS) and ketamine (60 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA) anesthesia. Surgery occurred at least 1 week before initiation of experimental protocol.
E 2 administration
In Experiment 1, OVX rats were chronically implanted with two silastic capsules filled with 17β-E 2 (Steraloids, Newport, RI). In Experiment 2, a more physiological regimen of E 2 was utilized to mimic endogenous fluctuations over the estrous cycle of rats and determine potential dose-dependent effects of E 2 . OVX rats were administered a vegetable oil vehicle (0.2 cc) or a low (0.03 mg/kg) or moderate (0.09 mg/kg) dosage of E 2 , once weekly for 3.5 months. This injection regimen was based upon our previous investigation of dose-dependent effects of E 2 . We found that 0.06-0.09 mg/kg E 2 SC to young, OVX rats 44-48 h before behavioral testing is effective at producing physiological levels of E 2 in plasma, akin to those observed when rats are naturally sexually receptive, and enhancing affective and sexual responding of rats (Frye et al. 1998; Walf and Frye 2005b) . Sexual behavior testing occurred during week 6 of the protocol.
DMBA administration
In Experiment 2, rats were administered an inert control substance (i.e., vegetable oil) or the chemical carcinogen DMBA (Sigma, St. Louis, MO). DMBA was dissolved in vegetable oil to the following concentrations: 1.25, 12.50, or 25.00 mg (based upon Constantinou et al. 2001) . DMBA was administered by gavage, using a needle that was 16-gauge, curved, 3 inches long, and had a 3 mm diameter ball on the end. Rats received a single administration of DMBA or vehicle.
Behavioral testing
In Experiment 2, rats were tested once to assess sexual behavior during week 6 of the protocol. Rats were tested for sexual behavior in a Plexiglas chamber (50×25× 30 cm) using previously described methods (Frye et al. 1998; Walf and Frye 2005b) . The frequency of lordosis (lordosis quotient; LQ) exhibited by experimental female rats was recorded for 10 mounts or 10 min, whichever occurred first.
Proliferation measures and tissue collection
Proliferation measures were based upon tumorigenesis (incidence of tumor per group, number of tumors, mean wet weight of tumors) and uterine weight. Rats were euthanized by rapid decapitation. Rats were palpated and visually inspected during necropsy to determine presence of tumors. If tumors were present, they were dissected out, counted, and weighed. Uteri (not including fallopian tubes) of each rat were dissected out and weighed.
Statistical analyses
In Experiment 1, one-way analyses of variance tests (ANOVAs) were utilized to determine effects of the E 2 condition on uterine weights. In Experiment 2, two-way ANOVAs were utilized to determine the effects of E 2 dosage and DMBA dosage on all endpoints. If main effects were found, group differences were determined by Fisher's post hoc tests. A P-value of ≤0.05 was considered significant and ≤0.10 a tendency.
Results

Experiment 1
There was an increased incidence of tumors among rats that were administered E 2 for 6 months compared to those administered E 2 for 2 months or vehicle (Fig. 1) . Among rats administered E 2 for 6 months with tumors, the average weight of these was 0.54 grams (± 0.31 SEM). Rats administered E 2 for 6 months had increased uterine weights compared to those administered short term E 2 or vehicle [F(2,11)= 8.19, P<0.01] (Fig. 1) .
Experiment 2
The incidence of rats developing tumors based upon E 2 and DMBA dosage is depicted in Fig. 2 . There was a significant main effect of DMBA administration to increase mean number of tumors [F(3,40 (Fig. 2) . Compared to vehicle, 0.03 or 0.09 mg/kg E 2 increased uterine weights to a similar extent as DMBA administration.
Lordosis quotients of rats were altered by E 2 , but not DMBA administration (Fig. 3) . There was a significant main effect of E 2 administration to increase [F(2,40)= 27.38, P<0.01] LQ. Compared to vehicle, 0.03 or 0.09 mg/kg E 2 increased LQ. Fig. 1 Tumor incidence (top) and uterine weight (bottom; means in grams ± SEM) of ovariectomized (OVX) rats administered estradiol (E 2 ) for 0, 2, or 6 months. * Significant (P≤0.05) effect of E 2 regimen vs other conditions
Discussion
The results of the present study partially supported our hypothesis that duration and dosing of E 2 exposure would alter proliferation, and that E 2 would increase sexual behavior of OVX rats. Exposure of OVX rats to E 2 for 6 months increased tumor incidence and uterine weights compared to E 2 for 2 months or no such exposure. E 2 had similar effects when administered for 3.5 months in Experiment 2. Specifically, both dosages of E 2 enhanced sexual receptivity (i.e., lordosis in response to mounting by a male rat) compared to vehicle. Compared to no carcinogen exposure, rats administered DMBA had increased incidence, number, and weight of tumors. Irrespective of dose, E 2 increased tumor number and weight compared to vehicle. Compared to vehicle, both dosages of E 2 similarly increased uterine weight, irrespective of DMBA dosage. Taken together, these data suggest that E 2 has effects to increase sexual behavior of OVX rats as well as having detrimental trophic effects.
The current findings confirm previous data on the effects of E 2 on tumorigenic processes in animal models. Consistent with our results, administration of high dosages of E 2 benzoate via chronic SC implants produces mammary gland proliferation at 13 weeks and palpable tumors at 20 weeks following initiation of E 2 treatment in OVX Noble rats (Leung et al. 2003) . In the present study, we found that tumor incidence was increased in OVX Long-Evans rats administered chronic E 2 for 6 months, compared to 2 months or no such E 2 exposure. In the follow-up experiment, we found that E 2 increased tumor burden among OVX rats, and, although not significant, there were apparent modest effects of E 2 on augmenting the effects of DMBA with respect to tumor burden. There was no clear interaction between E 2 and DMBA dosing because E 2 similarly increased tumorigenesis at each level of DMBA. DMBA itself increased tumorigenesis and uterine weights. Although the lowest dosage of DMBA produced tumors with the highest weights, other measures of tumorigenesis, such as incidence of tumors per group and number of tumors, demonstrated the more expected pattern of higher dosing of DMBA producing more robust effects. Other studies have demonstrated that DMBA reliably produces tumors, which are mostly adenocarcinomas and hormone-dependent (Cheung et al. 2003; Russo et al. 1990; Russo 1996, 1998) . Dietary exposure of E 2 to OVX Big Blue transgenic rats that were exposed to DMBA increased uterine dysplasia and cell proliferation (Aidoo et al. 2005) . Hemiovariectomized rats administered DMBA and E 2 pellets had mammary dysplasia 3 and 6 months following initiation of treatment, whereas dysplasia was only noted at 6 months following treatment with DMBA alone (Ting et al. 2007) . Furthermore, the effect of E 2 to increase mammary tumors following DMBA administration is not observed in animals that do not develop a mature hypothalamic-pituitary-gonadal axis (i.e., those that are castrated before puberty; Callejo et al. 2005 ). This suggests that prior E 2 exposure is an important variable in this model. Together, these data confirm that E 2 has trophic effects in animal models of hormone-dependent cancer.
In addition to confirming previously published findings on the effects of E 2 , the current findings extend these results by concomitantly investigating behavioral and tumorigenic processes in a whole animal model. The present data confirm the well-known effects of E 2 in promoting sexual response of OVX female rats. Although other studies have separately investigated the effects of E 2 on psychological symptoms and trophic effects, it is becoming increasingly important to look at both of these processes. Indeed, expression of steroid receptors in mammary glands of women with breast cancer may be associated with psychological symptoms (Razavi et al. 1990 ). Furthermore, the role of ovarian steroids, such as progesterone and its metabolites, needs to be taken into consideration. This may be particularly important because E 2 increases formation of progesterone's metabolites, and thus can enhance its functional effects (Cheng and Karavolas 1973; Rhodes and Frye 2005; Vongher and Frye 1999) . We and others have demonstrated the robust effects that E 2 as well as progesterone and its metabolites have on affective and socio-sexual behavior (reviewed in Walf and Frye 2006; reviewed in Frye et al. 2006 ). As such, Fig. 3 Mean (± SEM) lordosis quotients (LQ) of OVX rats administered estradiol (E 2 ) and/or the chemical carcinogen DMBA. * Significant (P≤ 0.05) effect of E 2 vs vehicle investigating concomitant changes in psychological/ behavioral effects and trophic effects of E 2 and how these effects may be altered by other steroids is timely and clinically relevant. Of interest would be to further investigate these effects in our model using older, anestrous or OVX rats, or with clinically utilized E 2 -based therapies. In the present study, it was necessary to determine the dose-dependent effects of E 2 -a primary estrogen secreted by the ovaries of women and rodents. However, although the regimen utilized was physiological to rats, women are not prescribed E 2 and would typically be administered more chronic (not once weekly) dosing of E 2 -based therapies, such as conjugated equine estrogens. Although few studies have investigated the effects of conjugated equine estrogens in rodent models of breast cancer, mammary carcinogenesis was increased in OVX rats administered conjugated equine estrogens alone or with a commonly prescribed progestin therapy, medroxyprogesterone acetate (Sakamoto et al. 1997) . Future studies will further investigate the role and mechanisms of E 2 and E 2 -based therapies for these effects on behavior and proliferation.
An important topic in investigation of the therapeutic efficacy of E 2 is related to the differential distribution and actions of its cognate receptors, ERα and ERβ. Compared to ERα, ERβ is not highly concentrated in peripheral tissues (uterus, breast) that are sensitive to the proliferative/carcinogenic effects of E 2 (as reviewed in Gustafsson 2003) . Importantly, ERβ is more widely distributed in the limbic regions of the brain, such as the hippocampus, which may account for some of the beneficial effects associated with this receptor subtype for affective and cognitive behavior (Shughrue et al. 1997; reviewed in Walf and Frye 2006) . ERβ expression may be associated with better prognosis among women with breast cancer (reviewed in Shupnik 2007; Sugiura et al. 2007 ). Furthermore, the interaction between ERα and ERβ and/or other "non-genomic" membrane actions (e.g., GPR30) and/or downstream signaling pathways (e.g., MNAR; reviewed in Cheskis et al. 2007; 2008) are of interest in terms of the diverse actions of E 2 on the heart (myocytes, anti-apoptotic actions, nitric oxide synthesis, Ca ++ channels, fibroblasts, anti-proliferation), liver (increase HDL, decrease LDL, increase CRP), blood vessels (vascular tone, anti-oxidant, atherosclerosis, angiogenesis), breast and uterus (proliferative, angiogenic), bone (proliferative), and CNS (trophic, antiapoptotic). Indeed, it is critical to discern the receptor mechanisms that are important for beneficial vs unwanted proliferative effects of E 2 in future studies utilizing our model.
